New Triple-Drug combo could outsmart Drug-Resistant malaria
NCT ID NCT05951595
Summary
This study is testing a new triple-drug combination therapy (ALAQ) to see if it works as well as or better than current two-drug standard treatments for uncomplicated malaria. It will enroll 1,680 patients in Africa and Asia who will be randomly assigned to receive either the new triple therapy or one of the standard treatments. The main goal is to see if the new combination is as effective, safe, and tolerable over 42 days of follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNCOMPLICATED PLASMODIUM FALCIPARUM MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruhuha Health Centre
RECRUITINGRuhuha, Eastern Province, Rwanda
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.